enzastaurin

enzastaurin information and resources from the National Cancer Institute

enzastaurin

A synthetic macrocyclic bisindolemaleimide. Binding to the ATP-binding site, LY317615 selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden. enzastaurin

A synthetic macrocyclic bisindolemaleimide. Binding to the ATP-binding site, LY317615 selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden.

Lilly launches Phase III trial of Enzastaurin Mar 9, 2006
Reuters ...(LLY.N: Quote, Profile, Research) on Thursday said it had initiated a Phase III trial of its Enzastaurin investigational targeted oral agent for treating ...

Lilly starts phase 3 trial of enzastaurin Mar 9, 2006
United Press International INDIANAPOLIS, March 9 (UPI) -- Eli Lilly said Thursday it initiated a phase 3 trial of enzastaurin for treatment of a rare brain cancer. ...

Lilly launches phase III trial of Enzastaurin Mar 9, 2006
News-Medical.net, Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme ...

Eli Lilly Launches Phase III Study Of Enzastaurin For Brain Tumor ... Mar 9, 2006
Trading Markets, Indiana-based pharmaceutical company Eli Lilly and Company (LLY | charts | news | Powerrating) announced the launch of Phase III study of Enzastaurin for the ...

Lilly Conducts Clinical Trial For Treatement of Rare Form of ... Mar 9, 2006
Inside INdiana Business (press release), 100 sites worldwide. The company says Enzastaurin, an oral treatment, attacks the tumor in several ways. Glioblastoma multiforme ...

Lilly Launches Phase III Trial of Targeted Cancer Agent Mar 9, 2006
news aktuell (Pressemitteilung), Indianapolis (ots/PRNewswire) - - Enzastaurin Study Enrolling Patients with Glioblastoma One of the deadliest and rarest forms of cancer is the focus of a ...

Eli Lilly Launches Phase III Study Of Investigational Agent To ... Mar 9, 2006
Trading Markets, ...(RTTNews) - Eli Lilly & Co. (LLY | charts | news | Powerrating) launches the Phase III study of Enzastaurin, an investigational oral agent for the treatment of ...

Lilly launches phase III trial in aggressive brain cancer Mar 10, 2006
Pharmaceutical Business Review Eli Lilly has launched a phase III trial of enzastaurin, an investigational oral agent for the treatment of relapsed glioblastoma multiforme, an aggressive and ...

Lilly begins large brain cancer trial Mar 9, 2006
BusinessWeek ...sites will participate in the study to treat glioblastoma multiforme, a particularly aggressive form of brain cancer, with its drug candidate enzastaurin. ...

Markets Hobnob With Multi-year Highs; Nasdaq Lags Mar 18, 2006
Trading Markets, ...ovarian cancer. In another news, the company said it is launching Phase III study of brain tumor treatment Enzastaurin. Late Sunday ...

Stocks may rise on BOJ's policy move Mar 9, 2006
BusinessWeek ...said that it has launched a phase III trial of Enzastaurin, an investigational, targeted, oral agent for the treatment of brain cancer. ...

Eli lilly and company Mar 9, 2006
ANP Pers Support, While there have been some recent advances in treating this. devastating disease, survival rates are still low. Enzastaurin is a promising agent, and. ...

enzastaurin -->